Tofacitinib is a small-molecule targeted synthetic DMARD. It was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling (inhibition of janus kinases). Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic DMARD or in monotherapy. It inhibits radiographic progression of the disease. Also it has a safety profile of more than 9.5 years.
In the treatment of adult patients with moderate to severe active rheumatoid arthritis